NCT06970275 To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
| NCT ID | NCT06970275 |
| Status | Recruiting |
| Phase | — |
| Sponsor | XEOS Medical |
| Condition | Prostate Cancers |
| Study Type | OBSERVATIONAL |
| Enrollment | 850 participants |
| Start Date | 2025-11-19 |
| Primary Completion | 2031-01-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 850 participants in total. It began in 2025-11-19 with a primary completion date of 2031-01-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This registry study aims to evaluate the effectiveness and clinical impact of specimen PET-CT imaging by analyzing the correlation between specimen PET-CT images, intraoperative interpretations, and histopathological findings. Additionally, it assesses how these imaging insights influence clinical decision-making and long-term patient outcomes. Through this comprehensive analysis in a real-world setting, the study seeks to generate valuable insights that can enhance specimen evaluation processes and ultimately improve patient care.
Eligibility Criteria
Inclusion Criteria : All patients that were scheduled for resective surgery and for whom successful high-resolution PET-CT imaging was performed on their resected specimens using the AURA 10 PET-CT. Successful imaging means that the image contains at least a portion of the primary tumor, the radiotracer injection was correctly executed and there were no technical issues that lead to an uninterpretable PET-CT image. Or all patients that are scheduled for resective surgery and for whom high-resolution PET-CT imaging will be performed on their resected specimens using the AURA 10 PET-CT. Patients willing to provide informed consent for use of their relevant medical records. For retrospectively included patients with no further Long-Term Follow-Up (LTFU) data collection, a notification will be sent. Exclusion Criteria: * Under the age of 18 years at the time of resective surgery. * Women who are pregnant or breastfeeding.
Frequently Asked Questions
Who can join the NCT06970275 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Prostate Cancers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06970275 currently recruiting?
Yes, NCT06970275 is actively recruiting participants. Visit ClinicalTrials.gov or contact XEOS Medical to inquire about joining.
Where is the NCT06970275 trial being conducted?
This trial is being conducted at Ghent, Belgium.
Who is sponsoring the NCT06970275 clinical trial?
NCT06970275 is sponsored by XEOS Medical. The trial plans to enroll 850 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.